ProQR Therapeutics (PRQR) Non Operating Income (2013 - 2026)

ProQR Therapeutics has reported Non Operating Income for 14 years, with the latest figure at $248198.1 in Q1 2026.

• Quarterly Non Operating Income rose 146.45% year-over-year to $248198.1 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258512.5 (up 8498.64% YoY) and the FY2021 annual result came in at $3.3 million, up 177.79% from the prior year.
• Non Operating Income declined to $248198.1 in Q1 2026 per PRQR's latest filing, from $327335.4 in the prior quarter.
• Over five years, Non Operating Income peaked at $1.4 million in Q1 2022 and troughed at -$583897.9 in Q1 2023.
• A 5-year average of $336684.4 and a median of $395158.3 in 2023 frame the typical range for Non Operating Income.
• The sharpest annual moves came in 2022 and 2023: Non Operating Income jumped 499.81% in 2022, then slumped 141.32% in 2023.
• Over 5 years, Non Operating Income stood at $603956.3 in 2022, then sank by 34.57% to $395158.3 in 2023, then jumped by 30.34% to $515064.9 in 2024, then slumped by 36.45% to $327335.4 in 2025, then dropped by 24.18% to $248198.1 in 2026.
• According to Business Quant data, Non Operating Income over the past three periods registered $248198.1, $327335.4, and $217336.3 for Q1 2026, Q3 2025, and Q2 2025 respectively.